TMAO challenge increased phospho-ERK1/2 levels in a time- (Fig. 5B) and dose-dependent (Fig. 5C and Supplementary Fig. 8A) manner, at concentrations (10–100 μM) relevant to human disease (up to 150 μM in patients with CKD)19. The gene discussed is MAPK3; the disease is chronic kidney disease.